{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:33:59Z","timestamp":1777660439129,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HAB"],"published-print":{"date-parts":[[2021,11,22]]},"abstract":"<jats:p>This study aimed to evaluate the prognostic value of baseline macrophage inflammatory protein (MIP)-1\u03b2\/IL12p40 ratio for antiviral treatment outcome in HCV genotype 4 patients. METHODS: Sera of 450 treatment-na\u00efve chronic HCV patients and 50 healthy individuals were collected. Liver transaminases, total bilirubin and albumin were biochemically tested, viral RNA was quantified, and circulating MIP-1\u03b2 and IL-12p40 were estimated using human anti-MIP-1\u03b2 and IL-12p40 antibodies in Sandwich ELISA. RESULTS : No difference was observed in the baseline chemokines levels between responders and relapsers, but the later had a significantly higher MIP-1\u03b2\/IL-12p40 ratio (P&lt; 0.0001). Multivariate regression analysis of baseline characteristics showed that gender, age, viral load, albumin level and chemokine ratios can significantly predict treatment outcome (P= 0.0114, 0.0095, 0.042, 0.0004 and &lt; 0.0001; respectively). Accordingly, a predictive threshold of baseline chemokine ratio was calculated and it showed an AUC of 0.6917 (P= 0.0108; 95% CI: 0.5566 to 0.8268). The calculated threshold for predicting virologic response was 8.245, with positive and negative predictive values of 92.98% and 100%; respectively. The chemokine ratios had significant correlations with liver transaminases in treated groups whether pre or post-treatment. CONCLUSION: Baseline MIP-1\u03b2\/IL-12p40 ratio represents a non-invasive prognostic biomarker that would provide shorter treatment duration and minimizes the emergence of drug-resistant variants in HCV genotype 4-patients.<\/jats:p>","DOI":"10.3233\/hab-211504","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T11:09:28Z","timestamp":1631012968000},"page":"263-274","source":"Crossref","is-referenced-by-count":1,"title":["Circulating macrophage inflammatory protein-1\u03b2\/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients"],"prefix":"10.1177","volume":"29","author":[{"given":"Heba","family":"Shawky","sequence":"first","affiliation":[{"name":"Therapeutic Chemistry Department, Division of Pharmaceutical Industries and Drug Research, National Research Centre, Dokki, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"El-Shenawy","sequence":"additional","affiliation":[{"name":"Microbial Biotechnology Department, Division of Genetic Engineering and Biotechnology, National Research Centre, Dokki, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiera M.","family":"Helmy","sequence":"additional","affiliation":[{"name":"Microbial Biotechnology Department, Division of Genetic Engineering and Biotechnology, National Research Centre, Dokki, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/HAB-211504_ref2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/HMER.S113681","article-title":"Hepatitis C infection in Egypt: Prevalence, impact and management strategies","volume":"9","author":"Gomaa","year":"2017","journal-title":"Hepat Med"},{"issue":"12","key":"10.3233\/HAB-211504_ref4","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1056\/nejmsr1912628","article-title":"Screening and treatment program to eliminate hepatitis C in Egypt","volume":"382","author":"Waked","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.3233\/HAB-211504_ref5","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jhep.2015.08.010","article-title":"Management of direct-acting antiviral agent failures","volume":"63","author":"Buti","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.3233\/HAB-211504_ref6","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3892\/mmr.2017.6351","article-title":"Viral and host factors associated with outcomes of hepatitis C virus infection","volume":"15","author":"Yan","year":"2017","journal-title":"Mol. Med. Rep"},{"key":"10.3233\/HAB-211504_ref7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.antiviral.2011.08.009","article-title":"The effect of cytokine profiles on the viral response to re-treatment in antiviral-experienced patients with chronic hepatitis C virus infection","volume":"92","author":"Zhang","year":"2011","journal-title":"Antiviral Res"},{"issue":"12","key":"10.3233\/HAB-211504_ref8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2217\/fvl.14.89","article-title":"Hepatitis C virus, strategies to evade antiviral responses","volume":"9","author":"Gokhale","year":"2014","journal-title":"Fut. Virol"},{"key":"10.3233\/HAB-211504_ref9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1365-2893.2006.00838.x","article-title":"The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection","volume":"14","author":"Zeremski","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.3233\/HAB-211504_ref10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/cmi.2013.37","article-title":"The role of chemokines in acute and chronic hepatitis C infection","volume":"11","author":"Fahey","year":"2014","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"10.3233\/HAB-211504_ref11","doi-asserted-by":"publisher","first-page":"e0154815","DOI":"10.1371\/journal.pone.0154815","article-title":"Overrepresentation of IL-10-expressing B cells suppresses cytotoxic CD4+ T cell activity in HBV-induced hepatocellular carcinoma","volume":"11","author":"Xue","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.3233\/HAB-211504_ref12","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cyto.2012.07.017","article-title":"Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma","volume":"60","author":"Jang","year":"2012","journal-title":"Cytokine"},{"issue":"1","key":"10.3233\/HAB-211504_ref13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12879-019-4130-0","article-title":"Potential circulating biomarkers of circulating chemokines CCL5, MIP-1\u03b2 and HA as for early detection of cirrhosis related to chronic HBV (hepatitis B virus) infection","volume":"19","author":"Hu","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.3233\/HAB-211504_ref14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijid.2014.08.021","article-title":"Pretreatment serum macrophage inflammatory protein (MIP)-1 levels predict sustained virological responses to re-treatment in patients with chronic hepatitis C virus infection","volume":"33","author":"Zhang","year":"2015","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.3233\/HAB-211504_ref15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3851\/imp1869","article-title":"Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: Pretreatment prediction of treatment failure in chronic hepatitis C","volume":"16","author":"Umemura","year":"2011","journal-title":"Antivir Ther"},{"key":"10.3233\/HAB-211504_ref16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00705-016-3059-5","article-title":"A simple real-time polymerase chain reaction assay using SYBR green for hepatitis C virus genotyping","volume":"162","author":"Zaghloul","year":"2017","journal-title":"Arch Virol"},{"issue":"3","key":"10.3233\/HAB-211504_ref17","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1128\/JCM.33.3.654-657.1995","article-title":"Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: Comparison with nested amplification and antibody testing","volume":"33","author":"Young","year":"1995","journal-title":"J Clin Microbial"},{"key":"10.3233\/HAB-211504_ref18","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1128\/2FAAC.01229-15","article-title":"Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with Ombitasvir plus Paritaprevir\/Ritonavir","volume":"59","author":"Schnell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.3233\/HAB-211504_ref19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s43066-021-00080-0","article-title":"NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy","volume":"11","author":"Makhlouf","year":"2021","journal-title":"Egypt Liver Journal"},{"issue":"5","key":"10.3233\/HAB-211504_ref20","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jhep.2018.07.02","article-title":"Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection","volume":"69","author":"Vermehren","year":"2018","journal-title":"J Hepatol"},{"key":"10.3233\/HAB-211504_ref21","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1099\/vir.0.82626-0","article-title":"Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma","volume":"88","author":"Abdel-Hamid","year":"2007","journal-title":"J Gen Virol"},{"key":"10.3233\/HAB-211504_ref22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cyto.2011.10.020","article-title":"High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV\/HCV co-infected patients","volume":"57","author":"Berenguer","year":"2012","journal-title":"Cytokine"},{"key":"10.3233\/HAB-211504_ref23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1574886314666191001151314","article-title":"Ledipasvir\/sofosbuvir versus daclatasvir\/sofosbuvir for the treatment of chronic hepatitis C genotype 4 patients","volume":"15","author":"Abdelaty","year":"2020","journal-title":"Current Drug Safety"},{"key":"10.3233\/HAB-211504_ref24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/mmj.mmj_95_19","article-title":"Study the efficacy of sofosbuvir\/daclatasvir in treatment of hepatitis C virus in Egypt","volume":"33","author":"Nouh","year":"2020","journal-title":"Menoufia Med J"},{"issue":"1","key":"10.3233\/HAB-211504_ref25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12876-020-01196-0","article-title":"Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: A multicentre cohort study","volume":"20","author":"Charatcharoenwitthaya","year":"2020","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.3233\/HAB-211504_ref26","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1099\/jgv.0.000768","article-title":"Decreased pro-inflammatory immune responses during recurrent acute HCV infections in HIV co-infected patients","volume":"98","author":"Hullegie","year":"2017","journal-title":"J Gen Virol"},{"issue":"10","key":"10.3233\/HAB-211504_ref27","doi-asserted-by":"publisher","first-page":"e0186213","DOI":"10.1371\/journal.pone.0186213","article-title":"Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy","volume":"12","author":"Burchill","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"10.3233\/HAB-211504_ref28","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/infdis\/jiw457","article-title":"Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C","volume":"214","author":"Hengst","year":"2016","journal-title":"J Infect Dis"},{"issue":"2","key":"10.3233\/HAB-211504_ref29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/hep.22763","article-title":"Chemokines in the immune-pathogenesis of hepatitis C infection","volume":"49","author":"Heydtmann","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.3233\/HAB-211504_ref30","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3892\/mmr.2017.6351","article-title":"Viral and host factors associated with outcomes of hepatitis C virus infection (review)","volume":"15","author":"Yan","year":"2017","journal-title":"Molecular Medicine Reports"},{"issue":"3","key":"10.3233\/HAB-211504_ref31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1089\/vim.2017.0124","article-title":"Analysis of host and viral-related factors associated to direct acting antiviral response in hepatitis C virus patients","volume":"31","author":"Aziz","year":"2018","journal-title":"Viral Immunol"},{"issue":"2","key":"10.3233\/HAB-211504_ref32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.14740\/gr999w","article-title":"Direct-acting antivirals in chronic hepatitis C genotype 4 infection in community care setting","volume":"11","author":"Gayam","year":"2018","journal-title":"Gastroenterol. Res"},{"issue":"44","key":"10.3233\/HAB-211504_ref33","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.3748\/wjg.v25.i44.6551","article-title":"Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China","volume":"25","author":"Yang","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.3233\/HAB-211504_ref34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.20517\/2394-5079.2015.53","article-title":"Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study","volume":"2","author":"Belci","year":"2016","journal-title":"Hepatoma Res"},{"key":"10.3233\/HAB-211504_ref35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.antiviral.2017.02.001","article-title":"Strategies for serum chemokine\/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases","volume":"141","author":"Menezes","year":"2017","journal-title":"Antiviral Res"},{"issue":"3","key":"10.3233\/HAB-211504_ref36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1046\/j.1365-2893.2002.00354.x","article-title":"Increased serum levels of macrophage inflammatory protein-3alpha in chronic viral hepatitis: Prognostic importance of macrophage inflammatory protein-3alpha during interferon therapy in chronic hepatitis C","volume":"9","author":"Yamauchi","year":"2002","journal-title":"J Viral Hepat"},{"key":"10.3233\/HAB-211504_ref37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1155\/2FS0962935104000523","article-title":"Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C","author":"Nischalke","year":"2004","journal-title":"Mediators Inflamm"},{"issue":"6","key":"10.3233\/HAB-211504_ref38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/jac\/dkh239","article-title":"CC-chemokine receptor 5 (CCR5) in hepatitis C at the crossroads of the antiviral immune response","volume":"53","author":"Ahlenstiel","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.3233\/HAB-211504_ref39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2Fs12985-016-0482-x","article-title":"Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines\/chemokines during acute hepatitis C virus infection","author":"Hajarizadeh","year":"2016","journal-title":"Virol J"},{"issue":"42","key":"10.3233\/HAB-211504_ref40","doi-asserted-by":"publisher","first-page":"43479","DOI":"10.1074\/jbc.m407640200","article-title":"Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation","volume":"279","author":"Eisen-Vandervelde","year":"2004","journal-title":"J Biol Chem"}],"container-title":["Human Antibodies"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/HAB-211504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:22:30Z","timestamp":1777447350000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/HAB-211504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":38,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/hab-211504","relation":{},"ISSN":["1875-869X","1093-2607"],"issn-type":[{"value":"1875-869X","type":"electronic"},{"value":"1093-2607","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,22]]}}}